Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CLK3 antisense RNA 1 (CLK3-AS1) is presumed to be a long non-coding RNA, transcribed from the opposite strand of the *CLK3* gene locus. Antisense RNAs like CLK3-AS1 typically regulate the expression of their corresponding sense gene (here, CDC-like kinase 3 or CLK3) through direct interaction with mRNA, influencing its splicing, stability, or translation, or by recruiting chromatin modifiers to alter gene transcription[3][4]. There is no experimental or clinical evidence available that designates CLK3-AS1 as a therapeutic target, biomarker, or disease gene; further research is needed to establish any biological or pathological roles for this molecule.\nIf this query is intended for drug discovery or clinical context, “CLK3 antisense RNA 1 (CLK3-AS1)” should not be used as a canonical drug or receptor target entry.
no drug interacts with CLK3-AS1; antisense RNAs generally act by RNA-RNA base pairing and gene transcription regulation[3]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CLK3 antisense RNA 1 (CLK3-AS1).